Novartis (OTCPK:NVSE.F) - Cotización, noticias y análisis

Resumen de acción NVSE.F

Novartis AG se dedica a la investigación, desarrollo, fabricación y comercialización de productos sanitarios en Suiza y a escala internacional.

Acerca de la empresa

NVSE.F fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	2/6
Past Performance	5/6
Financial Health	4/6
Dividends	5/6

Recompensas

Cotiza un 55.6% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 10%

Los beneficios aumentaron un 52.4% el pasado año

Paga dividendo fiable de 3.7%

Análisis de riesgos

Grandes partidas extraordinarias que afectan a los resultados financieros

Competidores de Novartis AG

Johnson & Johnson

NYSE:JNJ

US$357.6b

Merck

NYSE:MRK

US$323.1b

Zoetis

NYSE:ZTS

US$75.7b

Eli Lilly

NYSE:LLY

US$690.3b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Novartis
Historical stock prices
Current Share Price	CHF95.23
52 Week High	CHF109.00
52 Week Low	CHF90.24
Beta	0.47
1 Month Change	0.34%
3 Month Change	-7.43%
1 Year Change	-10.58%
3 Year Change	10.50%
5 Year Change	18.14%
Change since IPO	136.60%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	NVSE.F	US Pharmaceuticals	Mercado US
7D	-0.8%	2.3%	1.6%
1Y	-10.6%	10.8%	25.1%

Rentabilidad vs. Industria: NVSE.F obtuvo unos resultados inferiores a los del sector US Pharmaceuticals , que el año pasado arrojó un rendimiento del 9.5%.

Rentabilidad vs. Mercado: NVSE.F obtuvo unos resultados inferiores a los del mercado US, que fue del 24.9% el año pasado.

Volatilidad de los precios

Is NVSE.F's price volatile compared to industry and market?
NVSE.F volatility
NVSE.F Average Weekly Movement	4.9%
Pharmaceuticals Industry Average Movement	10.2%
Market Average Movement	6.1%
10% most volatile stocks in US Market	16.7%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: NVSE.F no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de NVSE.F (5%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1996	76,057	Vas Narasimhan	www.novartis.com

Novartis AG se dedica a la investigación, desarrollo, fabricación y comercialización de productos sanitarios en Suiza y a escala internacional. La empresa ofrece medicamentos con receta para pacientes y médicos. Se centra en áreas terapéuticas como cardiovascular, renal y metabólica, inmunología, neurociencia y oncología, así como oftalmología y hematología.

Resumen de fundamentos de Novartis AG

¿Cómo se comparan los beneficios e ingresos de Novartis con su capitalización de mercado?
Estadísticas fundamentales de NVSE.F
Capitalización bursátil	US$198.31b
Beneficios(TTM)	US$9.11b
Ingresos (TTM)	US$47.73b

21.8x

Ratio precio-beneficio (PE)

4.2x

Ratio precio-ventas (PS)

¿Está NVSE.F sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de NVSE.F
Ingresos	US$47.73b
Coste de los ingresos	US$12.12b
Beneficio bruto	US$35.61b
Otros gastos	US$26.51b
Beneficios	US$9.11b

Últimos beneficios comunicados

Mar 31, 2024

Próxima fecha de beneficios

Jul 18, 2024

Beneficios por acción (BPA)	4.46
Margen bruto	74.61%
Margen de beneficio neto	19.08%
Ratio deuda/patrimonio	64.2%

¿Cómo se ha desempeñado NVSE.F a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

3.7%

Rentabilidad actual por dividendo

89%

Ratio de pagos

Resumen de acción NVSE.F

Recompensas

Análisis de riesgos

Competidores de Novartis AG

NYSE:JNJ

US$357.6b

NYSE:MRK

US$323.1b

NYSE:ZTS

US$75.7b

NYSE:LLY

US$690.3b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Novartis AG (SWX:NOVN) entered into an agreement to acquire Mariana Oncology, Inc. from Atlas Venture L.P., Access Biotechnology, RA Capital Management, L.P., Deep Track Capital, LP, Forbion Capital Partners B.V. and others for $1.8 billion.

Novartis and Medicines for Malaria Venture Announce Positive Efficacy and Safety Data for A Novel Treatment for Babies

Novartis AG Revise Earnings Guidance for the Year 2024

Novartis' Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthritis Treatment, While Pending Launch of UCB’s Bimzelx Poised to Further Disrupt the Market

Novartis Presents Results from Pre-Specified Interim Analysis of the Phase III APPLAUSE-IgAN study of Fabhalta

Novartis Fabhalta Receives Positive CHMP Opinion as First Oral Monotherapy for Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Recent updates

Novartis AG (SWX:NOVN) entered into an agreement to acquire Mariana Oncology, Inc. from Atlas Venture L.P., Access Biotechnology, RA Capital Management, L.P., Deep Track Capital, LP, Forbion Capital Partners B.V. and others for $1.8 billion.

Novartis and Medicines for Malaria Venture Announce Positive Efficacy and Safety Data for A Novel Treatment for Babies

Novartis AG Revise Earnings Guidance for the Year 2024

Novartis' Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthritis Treatment, While Pending Launch of UCB’s Bimzelx Poised to Further Disrupt the Market

Novartis Presents Results from Pre-Specified Interim Analysis of the Phase III APPLAUSE-IgAN study of Fabhalta

Novartis Fabhalta Receives Positive CHMP Opinion as First Oral Monotherapy for Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Novartis AG (SWX:NOVN) acquired IFM Due, Inc. from IFM Therapeutics, LLC for approximately $840 million.

Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India

Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm

Novartis AG Announces FDA Approves Xolair® (Omalizumab) as First and Only Medicine for Children and Adults with One or More Food Allergies

Novartis Reportedly in Lead to Acquire MorphoSys

Novartis AG Provides Earnings Guidance for the Year 2024

Novartis AG to Report Q1, 2024 Results on Apr 23, 2024

Novartis AG Presents Data from the Phase III NETTER-2 Trial

Novartis Pursuit of Cytokinetics Reportedly Cools

Novartis Reportedly in Advanced Talks to Buy Cytokinetics

Novartis AG Announces Positive Results from the Primary Analysis of ASC4FIRST

Novartis AG (SWX:NOVN) acquired SanReno Therapeutics from Pivotal bioVenture Partners China, Versant Venture Management, LLC, Samsara BioCapital LLC, Frazier Healthcare Partners managed by Frazier Management, L.L.C. and Frazier Life Sciences Management, LP.

Novartis Investigational Iptacopan Phase III Study Demonstrates Clinically Meaningful and Statistically Significant Proteinuria Reduction in Patients with C3 Glomerulopathy (C3G)

Latest Novartis Kisqali(R) Natalee Analysis Reinforces 25% Reduction in Risk of Recurrence Across Broad Population of Patients with Early Breast Cancer

Novartis Receives FDA Approval for Fabhalta (iptacopan) Offering Superior Hemoglobin Improvement in the Absence of Transfusions as the First Oral Monotherapy for Adults with PNH

Novartis AG to Report Q4, 2023 Results on Jan 31, 2024

Novartis Announces New Positive Data from the Phase III REMIX-1 and REMIX-2 Studies Investigating Remibrutinib

Novartis Announces US Food and Drug Administration Approves Cosentyx® to Treat Moderate to Severe Hidradenitis Suppurativa in Adults

Novartis Announces Positive Topline Results from the Interim Analysis of the Ongoing Pivotal Phase III ALIGN Study

Novartis AG Announces Impairment Charges for the Third Quarter of 2023

Novartis AG Raises Earnings Guidance for the Fiscal Year 2023

Novartis Kisqali Natalee Analysis Confirms Consistent Reduction in Risk of Recurrence Across Key Sub Groups of Patients with Early Breast Cancer

FDA Approves Novartis Cosentyx® as First Intravenous (Iv) Formulation Interleukin-17A Antagonist for Rheumatic Diseases

Novartis to Present New Oncology Data at ESMO 2023 Demonstrating Practice-Changing Innovation in Advanced Prostate and Early Breast Cancer

Novartis AG completed the Spin-Off of Sandoz Group AG (SWX:SDZ).

Bausch & Lomb Ireland completed the acquisition of ophthalmology assets of Novartis AG from Novartis AG for $2.5 billion.

Sandoz, Novartis Division, Receives European Commission Approval for Tyruko (Natalizumab), First and Only Biosimilar for Multiple Sclerosis in Europe

Novartis Radioligand Therapy Lutathera® Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival in First Line Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Novartis AG Issues Voluntary Nationwide Recall of One Lot of Sandimmune Oral Solution (cyclosporine oral solution, USP), 100 mg/mL due to Crystallization

Novartis AG Announces Executive Changes

Novartis Presents New Long-Term Leqvio (Inclisiran) Data Demonstrating Consistent Efficacy and Safety Beyond Six Years

Sandoz Announces Positive Results from Mylight Phase III Study for Biosimilar Aflibercept

Novartis AG (SWX:NOVN) completed the acquisition of Chinook Therapeutics, Inc. (NasdaqGS:KDNY) from a group of shareholders.

Novartis Ag Announces Positive Top-Line Results from the Phase Iii Remix-1 and Remix-2 Studies Evaluating Remibrutinib 25 Mg B.I.D

Novartis AG (SWX:NOVN) acquired DTx Pharma, Inc. for $1 billion.

US FDA Approves Expanded Indication for Novartis Leqvio® (Inclisiran) to Include Treatment of Adults with High LDL-C and Who Are at Increased Risk of Heart Disease

Bausch + Lomb Corporation (NYSE:BLCO) signed an agreement to acquire ophthalmology assets from Novartis AG (SWX:NOVN) for $2.5 billion.

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Novartis AG

21.8x

4.2x

Beneficios e Ingresos

Dividendos

3.7%

89%